Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren’t drugs at all, from smartphone apps and educational websites to social media platforms and…
From October 2010 to February 2011, biotech Clinical Data’s stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up — and making it likely to perhaps double again — is speculati…
To get potentially lifesaving drugs to patients faster, the U.S. Food and Drug Administration is allowed to approve some drugs — those that address unmet medical needs — based on fewer trials than usual. But it turns out that…
Diabetes is a growing global scourge, but for Big Pharma it’s more of a lifesaver — and many drugmakers are cranking up their research efforts. After all, many existing drugs will soon be losing their patents, and diabetes cou…
After several years of robust expansion, the leading branded pharma companies will see growth slow to just 1.3% from now to 2015, independent market analyst company Datamonitor said in a new report. The primary culprit: expirin…